Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb;3(1):1-8.
doi: 10.1016/j.jpha.2012.10.006. Epub 2012 Nov 7.

Quantitation of bivalirudin, a novel anticoagulant peptide, in human plasma by LC-MS/MS: Method development, validation and application to pharmacokinetics

Xiao-Jiao Li  1   2 , Yan-Tong Sun  1   2 , Lei Yin  1 , Xue-Ju Zhang  2 , Yan Yang  1   2 , J Paul Fawcett  3 , Yi-Min Cui  4 , Jing-Kai Gu  1   2
Affiliations

Quantitation of bivalirudin, a novel anticoagulant peptide, in human plasma by LC-MS/MS: Method development, validation and application to pharmacokinetics

Xiao-Jiao Li et al. J Pharm Anal. 2013 Feb.

Abstract

A rapid and sensitive method based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the determination of a novel anticoagulant peptide bivalirudin in human plasma has been developed and validated. Plasma samples were precipitated protein with acetonitrile and re-extracted with dichloromethane, after which the analyte and triptorelin as an internal standard (IS) were separated on a 300SB-C18 column (150 mm×4.6 mm i.d., 5 μm particle size) using 0.1% formic acid:methanol (45:55, v/v) as mobile phase. The triple-quadrupole mass spectrometer, equipped with electrospray ionization (ESI) interface, was operated in the positive ion mode, and the multiple-reaction monitoring (MRM) transitions of bivalirudin and IS were at m/z 1091.0→650.4 and m/z 656.5→249.3, respectively. The lower limit of quantification (LLOQ) was 1 ng/mL for 100 μL plasma sample and the assay was linear over the concentration range 1-1000 ng/mL. The accuracy was within a range from -0.4% to 0.5% in terms of relative error (RE) and the intra- and inter-day precisions in terms of relative standard deviation (RSD) were ≤2.92 and ≤3.36, respectively. The method was successfully applied to a pharmacokinetic study involving intravenous administration of bivalirudin (0.5 mg/kg) to Chinese volunteers.

Keywords: Anticoagulant; Bivalirudin; Human plasma; LC–MS/MS; Pharmacokinetics.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Q1 MS full-scan spectra of bivalirudin (A) and triptorelin (B).
Fig. 2
Fig. 2
Full-scan product ion spectra of [M+2H]2+ ions for bivalirudin (A) and triptorelin (B).
Fig. 3
Fig. 3
MRM chromatograms for bivalirudin[(A), (B), (C)] and triptorelin(IS)[(A′), (B′), (C′)] in human plasma samples. (A), (A′): a blank plasma sample; (B), (B′): a blank sample spiked with bivalirudin at the LLOQ (1 ng/mL) and IS (500 ng/mL); (C), (C′): a plasma sample from a human volunteer 1 h after intravenous administration of bivalirudin (0.5 mg/kg). Max is the maximum of the relative intensity.
Fig. 4
Fig. 4
Mean plasma concentration–time profile of bivalirudin after a single intravenous dose of 0.5 mg/kg (Data are mean±SD, n=9.).
None
See this image and copyright information in PMC

References

    1. Warkentin T.E. Bivalent direct thrombin inhibitors: hirudin and bivalirudin. Best Pract. Res. Clin. Haematol. 2004;17:105–125. - PubMed
    1. Lehman S.J., Chew D.P. Bivalirudin in percutaneous coronary intervention. J. Vasc. Health Risk Manage. 2006;2:357–363. - PMC - PubMed
    1. Rha S.W., Kuchulakanti P.K., Pakala R. Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent. Am. J. Cardiol. 2004;94:1047–1050. - PubMed
    1. Gladwell T.D. Bivalirudin: a direct thrombin inhibitor. Clin. Ther. 2002;24:38–58. - PubMed
    1. Gurm H.S., Rajagopal V., Fathi R. Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center. Am. J. Cardiol. 2005;95:716–721. - PubMed